InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe
July 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office (EPO). The patent provides additional protection for the use of cobitolimod in the treatment of inflammatory bowel disease.The patent, with patent number 3947685, will provide an exclusivity period until August 2040, with the possibility of up to 5 years term extension after market approval. “We are very pleased that the patent has been granted by the European Patent Office, which again confirms that